Phase 2 ventricular arrhythmias in acute myocardial infarction: a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology …
H Clements‐Jewery, DJ Hearse… - British journal of …, 2005 - Wiley Online Library
Ventricular fibrillation (VF), a cause of sudden cardiac death (SCD) in the setting of acute
myocardial infarction (MI), remains a major therapeutic challenge. In humans, VF may occur …
myocardial infarction (MI), remains a major therapeutic challenge. In humans, VF may occur …
Phase 2 ventricular arrhythmias in acute myocardial infarction: a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology …
H Clements-Jewery, DJ Hearse… - British journal of …, 2005 - pubmed.ncbi.nlm.nih.gov
Ventricular fibrillation (VF), a cause of sudden cardiac death (SCD) in the setting of acute
myocardial infarction (MI), remains a major therapeutic challenge. In humans, VF may occur …
myocardial infarction (MI), remains a major therapeutic challenge. In humans, VF may occur …
Phase 2 ventricular arrhythmias in acute myocardial infarction: a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology …
H Clements-Jewery, DJ Hearse… - British Journal of …, 2005 - kclpure.kcl.ac.uk
Ventricular fibrillation (VF), a cause of sudden cardiac death (SCD) in the setting of acute
myocardial infarction (MI), remains a major therapeutic challenge. In humans, VF may occur …
myocardial infarction (MI), remains a major therapeutic challenge. In humans, VF may occur …
Phase 2 ventricular arrhythmias in acute myocardial infarction: a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology …
H Clements-Jewery, DJ Hearse… - British Journal of …, 2005 - europepmc.org
Ventricular fibrillation (VF), a cause of sudden cardiac death (SCD) in the setting of acute
myocardial infarction (MI), remains a major therapeutic challenge. In humans, VF may occur …
myocardial infarction (MI), remains a major therapeutic challenge. In humans, VF may occur …
Phase 2 ventricular arrhythmias in acute myocardial infarction: a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology …
H Clements-Jewery, DJ Hearse… - British Journal of …, 2005 - search.proquest.com
Ventricular fibrillation (VF), a cause of sudden cardiac death (SCD) in the setting of acute
myocardial infarction (MI), remains a major therapeutic challenge. In humans, VF may occur …
myocardial infarction (MI), remains a major therapeutic challenge. In humans, VF may occur …
[引用][C] Phase 2 ventricular arrhythmias in acute myocardial infarction: a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology …
H CLEMENTS-JEWERY, DJ HEARSE… - British journal of …, 2005 - pascal-francis.inist.fr
Phase 2 ventricular arrhythmias in acute myocardial infarction : a neglected target for therapeutic
antiarrhythmic drug development and for safety pharmacology evaluation CNRS Inist …
antiarrhythmic drug development and for safety pharmacology evaluation CNRS Inist …
[HTML][HTML] Phase 2 ventricular arrhythmias in acute myocardial infarction: a neglected target for therapeutic antiarrhythmic drug development and for safety …
H Clements-Jewery, DJ Hearse… - British Journal of …, 2005 - ncbi.nlm.nih.gov
Ventricular fibrillation (VF), a cause of sudden cardiac death (SCD) in the setting of acute
myocardial infarction (MI), remains a major therapeutic challenge. In humans, VF may occur …
myocardial infarction (MI), remains a major therapeutic challenge. In humans, VF may occur …
Phase 2 ventricular arrhythmias in acute myocardial infarction: a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology …
H Clements-Jewery, DJ Hearse… - British Journal of …, 2005 - search.ebscohost.com
Ventricular fibrillation (VF), a cause of sudden cardiac death (SCD) in the setting of acute
myocardial infarction (MI), remains a major therapeutic challenge. In humans, VF may occur …
myocardial infarction (MI), remains a major therapeutic challenge. In humans, VF may occur …